


PHARMACEUTICAL 2021

Aquestive Therapeutics Inc. Rank 308 of 409









PHARMACEUTICAL 2021



Aquestive Therapeutics Inc. Rank 308 of 409

The relative strengths and weaknesses of Aquestive Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aquestive Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 108% points. The greatest weakness of Aquestive Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 201% points.

The company's Economic Capital Ratio, given in the ranking table, is -321%, being 34% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	44,625
Cost of Goods Sold	12,964
Intangible Assets	102
Liabilities, Current	21,104
Liabilities, Non-Current	8,424
Other Assets	11,284
Other Compr. Net Income	0
Other Expenses	13,022
Other Liabilities	81,853
Other Net Income	132
Property and Equipment	6,873
Research and Development	19,886
Revenues	45,849
Selling, General and Administrative Expense	55,892

Output Variable	Value in 1000 USD
Assets	62,884
Liabilities	111,381
Expenses	101,764
Stockholders Equity	-48,497
Net Income	-55,783
Comprehensive Net Income	-55,783
Economic Capital Ratio	-321%

